In a press release, the Serum Institute of India- world’s largest vaccine manufacturer announced that their ‘Covishield’ vaccine will be available at US$ 3 or Rs 225 per dose for India and other 92 low-and middle-income countries.
The Serum Institute of India has a manufacturing partnership for the Covid-19 vaccine by the Oxford University, and another one by a US-based company Novavax.
The vaccine candidate by Oxford University which showed promising results is under advanced stages of clinical trials in India and several other countries and is likely to be available for public use in the first half of 2021.
It is to be noted that the SII on Wednesday has signed a new partnership with Gavi, the Vaccine Alliance, and the Bill & Melinda Gates Foundation. The collaboration will provide upfront capital to SII to help them accelerate the manufacturing up to 100 million doses of COVID-19 vaccines for India and other -and middle-income countries, once the vaccine gains regulatory approval and WHO prequalification.
-By Shikhamoni Gogoi